Best Options Strategy for IMVT
Looking for the best options strategy for Immunovant, Inc. (IMVT)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live IMVT option chain right now, and a simple map from your view on IMVT to the strategy that fits it. Model any of them in the calculator before you trade.
About IMVT
Immunovant, Inc. (IMVT) is a major company in Biotechnology. Options traders on IMVT tend to watch , since these can drive large moves in the share price.
About Immunovant, Inc.
Immunovant is a clinical-stage biotech company focused on developing treatments for autoimmune diseases. Its primary candidate is IMVT-1402, a monoclonal antibody designed to block a specific immune pathway involved in several conditions. The company is investigating this single therapeutic approach across multiple autoimmune indications, including Graves' disease, rheumatoid arthritis, Sjögren's disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. Founded in 2018 and headquartered in Durham, North Carolina, Immunovant operates as a subsidiary within the Roivant Sciences portfolio.
Currently, Immunovant generates no revenue from product sales, as IMVT-1402 remains in clinical development and has not yet received regulatory approval. The company's finances depend on funding from its parent company, Roivant Sciences, which itself operates as a specialty biotech holding company. Immunovant's path to profitability is contingent on successfully advancing IMVT-1402 through late-stage clinical trials, obtaining FDA approval for one or more of its targeted indications, and eventually commercializing the therapy in markets where…
Today's top-scoring strategy for IMVT
Our engine ranks defined-risk strategies on the live IMVT chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $37 | $1.65 |
| Sell | 1× | PUT | $43 | $4.15 |
| Sell | 1× | CALL | $42 | $3.20 |
| Buy | 1× | CALL | $46 | $1.68 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $52 | $31 | $30 | $25 | $17 | $9 |
| $50 | $41 | $35 | $25 | $15 | $5 |
| $48 | $49 | $36 | $22 | $9 | −$2 |
| $46 | $52 | $32 | $15 | $1 | −$11 |
| $44 | $44 | $21 | $2 | −$12 | −$23 |
| $42 | $22 | $0 | −$16 | −$28 | −$38 |
| $40 | −$15 | −$29 | −$40 | −$49 | −$56 |
| $37 | −$61 | −$64 | −$69 | −$73 | −$77 |
| $35 | −$109 | −$102 | −$99 | −$98 | −$99 |
| $33 | −$150 | −$137 | −$129 | −$124 | −$121 |
| $31 | −$176 | −$164 | −$155 | −$147 | −$142 |
Live scan from 2026-08-14 · quotes delayed ~15 minutes
Historical backtest: how a Iron Butterfly on IMVT would have performed
We approximated a Iron Butterfly on IMVT, entered repeatedly over the past year (92 historical entries, each held to expiration) with Black-Scholes-modelled entry premiums. Here is how that would have played out on real IMVT price history — an educational backtest, not a prediction of future returns.
Approximate: entry premiums are modelled with Black-Scholes from trailing realised volatility, held to expiration and settled against the real historical close. Real fills, implied volatility and slippage differ — treat it as directional context, not exact returns.
Implied volatility
IMVT is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 65% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on IMVT currently price in about 65% implied volatility, versus roughly 35% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$8.33 (±20%) in IMVT by 2026-09-18 — a range of roughly $33.25 to $49.91. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on IMVT trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
IMVT options chain highlights: open interest, volume and skew
The live IMVT options chain shows a put/call open-interest ratio of 0.05 (bullish-leaning (more calls)), with at-the-money implied volatility near 64.7%. Open interest clusters at the $50 call — a common resistance "wall" — and the $25 put, a support "wall": the strikes option writers are most exposed to into expiration.
Snapshot of open interest, volume and implied volatility for the nearest scanned expiration — context, not a trading signal.
IMVT insider trading activity (SEC Form 4)
Open-market insider transactions at IMVT over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Pande Atul | Sell | 1,500 | $60K | 2026-07-24 |
| Stout Jay S | Sell | 2,857 | $111K | 2026-07-23 |
| Girao Tiago | Sell | 6,798 | $263K | 2026-07-23 |
| Gloria Melanie | Sell | 106 | $4K | 2026-07-08 |
| Gloria Melanie | Sell | 1,930 | $76K | 2026-07-08 |
| Van Tuyl Christopher | Sell | 63 | $3K | 2026-07-08 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Liquidity and tradeability
IMVT options are thinly traded, with wide bid-ask spreads around 50.5% near the money that eat into any edge — favour simple single-leg or tight defined-risk trades, and always use limit orders.
Key figures
- Market cap
- $8.0B
- Beta (vs market)
- 0.81
- 52-week range
- $14.32–$41.23 (100% up the range)
- Short interest
- 19.6% of float · 11.2 days to cover
With 19.6% of IMVT's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
Other strong setups for IMVT
If your view on IMVT differs, these also scored well in the latest scan:
How to choose an options strategy for IMVT
Start with your outlook on IMVT, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while IMVT stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open IMVT in the free calculator →
Frequently asked questions
What is the best options strategy for IMVT?
It depends on your outlook. Bullish traders often use a long call or bull call spread on IMVT; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are IMVT options liquid enough to trade?
Immunovant, Inc. (IMVT) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade IMVT options?
Buying a single IMVT call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade IMVT or any security. Do your own research.
What does Immunovant, Inc. do?
Immunovant, Inc. (IMVT) operates in the Biotechnology industry. The "About Immunovant, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Immunovant, Inc. pay a dividend?
We don't show a confirmed dividend yield for Immunovant, Inc. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
Price trend
Tickers related to IMVT
Comparing IMVT with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 1000 Park Forty Plaza, Suite 210, Durham, NC, 27713, United States
- Industry
- Biotechnology
- Employees
- 315
- CEO
- Dr. Eric Venker M.D., Pharm.D.
- Phone
- 917 410 3120
- Website
- immunovant.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.